We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Medtronic Pays $43M To Settle Shareholder Suit Over Infuse Bone Graft Studies

Mealey's (July 25, 2018, 12:44 PM EDT) -- MINNEAPOLIS — Medtronic Inc. and four individual defendants on July 1 agreed to a $43 million class settlement involving alleged securities violations related to Medtronic’s reporting of risks with the Infuse...
To view the full article, register now.